Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Epoetin Alfa

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.

            Lead Product(s): Erythropoietin EPO

            Therapeutic Area: Hematology Product Name: rHuEPO

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Blau Farmaceutica

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY